Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8101234 | 1.00 | SIGMAR1 (0.53) | SIGMAR1SLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL2080509 | 1.00 | SIGMAR1 (0.53) | SIGMAR1SLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL23496876 | 0.88 | SIGMAR1 (0.54) | SIGMAR1SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL6008090 | 0.88 | SIGMAR1 (0.54) | SIGMAR1SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL3948948 | 0.88 | SIGMAR1 (0.54) | SIGMAR1SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL10158913 | 0.86 | SPHK2 (0.46) | SIGMAR1SPHK2SPHK1 | |
| SCHEMBL1415727 | 0.86 | SLC6A2 (0.63) | SIGMAR1SLC6A2SLC6A4SLC6A3MITF | |
| SCHEMBL6936570 | 0.86 | SLC6A2 (0.63) | SIGMAR1SLC6A2SLC6A4SLC6A3MITF | |
| SCHEMBL27505917 | 0.86 | SLC6A2 (0.63) | SIGMAR1SLC6A2SLC6A4SLC6A3MITF | |
| SCHEMBL29247444 | 0.84 | SLC6A2 (0.50) | SIGMAR1SLC6A2SLC6A4SLC6A3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425649-A | Pyrazole derivatives as KRAS mutein inhibitors | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-1968962-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | Amgen Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| WO-2007070506-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | disclosed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | GLP1R, GPR119, INSR | SIGMAR1 565/4885SLC6A2 3182/4885SLC6A4 2423/4885 |
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | SIGMAR1 4509/4885SLC6A2 4403/4885SLC6A4 4307/4885 |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | SIGMAR1 4509/4885SLC6A2 4403/4885SLC6A4 4307/4885 |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | SIGMAR1 4509/4885SLC6A2 4403/4885SLC6A4 4307/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | SIGMAR1 4336/4885SLC6A2 2718/4885SLC6A4 2325/4885 |
| US-20060155121-A1 | Substituted aniline derivatives | UGT2B7, NAT1, CYP1A2 | SIGMAR1 441/4885SLC6A2 104/4885SLC6A4 208/4885 |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | SIGMAR1 3967/4885SLC6A2 3874/4885SLC6A4 3896/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | SIGMAR1 4509/4885SLC6A2 4403/4885SLC6A4 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.